Rutgers Cancer Institute | Strategic Alliance Partners

February 14, 2023

Alexey V. Danilov, MD, PhD, presents a second patient profile of a 60-year-old patient with MCL, and the panel discusses using CAR T-cell therapy to treat MCL.

February 07, 2023

A comprehensive discussion on ways to approach treating patients with high-risk mantle cell lymphoma.

February 07, 2023

A detailed look at how to select the appropriate BTK inhibitor to treat patients with MCL and the potential role of the non-covalent BTK inhibitor pirtobrutinib in MCL.

February 01, 2023

Howard S. Hochster, MD, discusses the evaluation of trastuzumab and pertuzumab vs cetuximab and irinotecan in HER2-amplified metastatic colorectal cancer.

January 31, 2023

Experts in hematologic malignancies review the role of BTK inhibitors and other therapies in patients with relapsed/refractory mantle cell lymphoma.

January 31, 2023

A panel of experts in hematologic malignancies discuss the SHINE study, which looked at ibrutinib with bendamustine and rituximab in elderly patients with MCL.

January 30, 2023

Mridula George, MD, discusses the methods used to evaluate cardiotoxicity associated with adjuvant trastuzumab emtansine plus concurrent radiation therapy, and explains implications on the use of trastuzumab emtansine plus radiation in patients with early-stage HER2-positive breast cancer.

January 12, 2023

Mridula George, MD, discusses the evaluation of cardiotoxicity associated with adjuvant trastuzumab emtansine with concurrent radiotherapy in patients with HER2-positive breast cancer.

October 17, 2022

Investigators from Rutgers Cancer Institute of New Jersey examined the microbiome of pancreatic tumors and identified particular microorganisms at single cell resolution that are associated with inflammation and with poor survival.

October 10, 2022

Further enhancing its focus on providing outstanding, innovative and compassionate care for cancer patients, Rutgers Cancer Institute of New Jersey, the state’s leading cancer center and only NCI-designated Comprehensive Cancer Center together with RWJBarnabas Health, are welcoming a new leader to its team of internationally recognized physicians and researchers.

September 20, 2022

State of Science Summit- Lung Cancer: Chaired by Missak Haigentz, MD Salma Jabbour, MD

September 15, 2022

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health have appointed Matthew Matasar, MD, MS, as Chief of Blood Disorders at New Jersey’s leading cancer center and the only one in the state designated as a Comprehensive Cancer Center by the National Cancer Institute.

September 04, 2022

Research published in 2022 has advanced our understanding of the effect of neoadjuvant therapy on organ preservation for patients with locally advanced rectal cancer.

August 30, 2022

Antoinette Stroup, PhD, shares personal and professional insight on the disaggregation of cancer health statistics regarding the Asian American and Pacific Islander community.

August 17, 2022

August 12, 2022

Joan Hogan, DSW, LCSW, OSW-C, and Rosemarie Slirzewski, MSW, LCSW, expand on the unique needs and challenges of LGBTQ+ individuals who are faced with cancer.

August 10, 2022

Robert Wood Johnson University Hospital, a RWJBarnabas Health facility, has been recognized as one of the top five hospitals in New Jersey and a top 20 Regional Best Hospital in the New York Metropolitan area by U.S. News & World Report in the annual Best Hospitals rankings.

August 01, 2022

Coral Omene, MD, PhD, medical oncologist in the Stacy Goldstein Breast Cancer Center at Rutgers Cancer Institute of New Jersey, the state’s only National Cancer Institute-designated Comprehensive Cancer Center together with RWJBarnabas Health, has been awarded a $50,000 grant from the V Foundation for Cancer Research in partnership with ESPN to increase clinical trial awareness and enrollment of Black women with breast cancer.

July 13, 2022

A world-class team of researchers assembled and led by Rutgers Cancer Institute of New Jersey and its Deputy Director and Chief Scientific Officer Eileen White, PhD, has been awarded a $25 million Cancer Grand Challenges grant to tackle the condition of cancer cachexia.

July 08, 2022

The Rutgers Board of Governors has named Rutgers Cancer Institute of New Jersey Deputy Director Eileen White, PhD, the Board of Governors Professor of Molecular Biology and Biochemistry at the Rutgers School of Arts and Sciences for her contributions to science and leadership in the fields of apoptosis, autophagy and cancer metabolism.